156 related articles for article (PubMed ID: 35099760)
1. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study.
Kitticharoenjit P; Supakul N; Rujkijyanont P; Traivaree C; Photia A; Monsereenusorn C
Asian Biomed (Res Rev News); 2021 Aug; 15(4):171-181. PubMed ID: 37551332
[TBL] [Abstract][Full Text] [Related]
3. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
7. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis.
Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O;
J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
9. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
[TBL] [Abstract][Full Text] [Related]
10. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
11. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: A single-center, 20-year experience.
Wang DS; Lu MY; Yang YL; Lin DT; Lin KH; Chang HH; Jou ST
J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):594-601. PubMed ID: 32741735
[TBL] [Abstract][Full Text] [Related]
13. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
15. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
[TBL] [Abstract][Full Text] [Related]
16. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
17. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
19. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis.
Monsereenusorn C; Suwannaying K; Buaboonnam J; Sathitsamitphong L; Techavichit P; Pakakasama S; Chainansamit SO; Anurathapan U; Komvilaisak P; Traivaree C; Sanpakit K; Charoenkwan P; Seksarn P
Asian Pac J Cancer Prev; 2024 May; 25(5):1831-1839. PubMed ID: 38809656
[TBL] [Abstract][Full Text] [Related]
20. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
